Cervical & ovarian cancer specialist Dr John Chia

Dr Choo Su Pin

Medical Oncologist

BMedSci, BMBS(Nottm), MRCP(UK), FAMS (Medical Oncology)

Biography

Dr Choo Su Pin is a senior medical oncologist with over 25 years of experience specialising in gastrointestinal cancers, including colorectal, stomach, pancreas, liver, bile duct, peritoneal and anal cancers. She is well recognised in Singapore and internationally for her clinical expertise, leadership in cancer care, and contributions to advancing treatments for GI cancers.

Before entering private practice, Dr Choo held several key leadership roles at the National Cancer Centre Singapore (NCCS), where she served as Deputy Head of the Division of Medical Oncology and Chief of the Gastrointestinal Cancer Department. She continues her longstanding relationship with NCCS as a Visiting Consultant

Dr Choo trained in the United Kingdom and Singapore, graduating from the University of Nottingham Medical School, and is a Fellow of the Royal College of Physicians (UK) and the Academy of Medicine, Singapore. She completed additional specialist training in medical oncology at NCCS and was selected for the competitive AACR/ASCO Clinical Cancer Research Workshop in the United States. She subsequently undertook a research fellowship at the University of California, San Francisco, where she contributed to clinical trials and research in GI cancers. She also holds a Graduate Diploma in Healthcare Management and Leadership from Singapore Management University.

Throughout her career, Dr Choo has played a role in developing Singapore’s oncology research programmes. She spearheaded the establishment of the Experimental Cancer Therapeutics Unit, which became a cornerstone for early-phase oncology drug development in Singapore. She also served as Co-Director of the Comprehensive Liver Cancer Clinic, Deputy Head of the Department of Clinical Trials and Epidemiological Sciences, and later Chair of the NCCS Clinical Trials Steering Committee, guiding scientific priorities and fostering a culture of innovation in clinical research. She helped establish the NCCS Gastrointestinal Cancer Database and was appointed as Adjunct Principal Investigator at the SingHealth Investigational Medicine Unit.

Dr Choo has contributed to many multinational cancer trials and earned competitive funding from agencies such as the National Medical Research Council and the Economic Development Board, both as principal investigator and co-investigator for research on gastrointestinal cancers and immune-oncology. She now continues to contribute to Singapore’s research landscape as Deputy Chair of the SingHealth Central Institutional Review Board, overseeing oncology trials across the SingHealth network.

Dr Choo’s academic footprint spans high-impact journals including The Lancet, Nature Genetics, Journal of Clinical Oncology, Annals of Oncology and Cancer Discovery. She is frequently invited to speak at international conferences and has helped shape clinical practice guidelines for liver and pancreatic cancers in the Asia-Pacific region. Her publications can be seen here: https://pubmed.ncbi.nlm.nih.gov/?term=choo+su+pin&filter=datesearch.y_10

A committed educator, Dr Choo is an Adjunct Associate Professor with the SingHealth Duke-NUS Oncology Academic Clinical Programme at Duke-NUS Medical School, and has previously held an adjunct appointment with the Yong Loo Lin School of Medicine. She remains deeply engaged in the training of oncology trainees and specialists, fostering the next generation of leaders in GI cancer care. Dr Choo has also been heavily involved in the organisation of major oncology conferences in the region

Within professional organisations, she holds prominent positions, including Censor-in-Chief of the Academy of Medicine, Singapore, and Honorary Secretary of the Chapter of Medical Oncology. She was the first female President of the Singapore Society of Oncology (SSO) and is a founding member of the SSO Cancer Immunotherapy Consortium.

Internationally, Dr Choo has served on advisory boards for pharmaceutical companies driving GI cancer drug development. She is a current faculty member in the European Society of Medical Oncology ( Lower GI track) which is involved in advanced oncology education and fostering global networks for cancer care, education and research. She also sits on the ESMO Women for Oncology Committee, where she advocates strongly for gender equity in the oncology profession. Dr Choo’s dream is for more equitable access to best cancer care across the globe especially in the ASEAN region

In Singapore, she volunteers her time as a Council Member of the Singapore Cancer Society where she chairs both the Cancer Research and the Community Partnership Committees. Thus, playing her part to help the society to fulfill its mission to reduce the impact of cancer and support patients and families.

Her contributions to clinical service and public health have been recognised with honours including the Gold Excellence Service Award and the National COVID-19 Award

Area of Interest

Gastrointestinal cancers

Curie Oncology Locations

Mount Elizabeth Novena Specialist Centre

Mount Elizabeth Medical Centre

Gleneagles Medical Centre

Publications

Media

胃癌误当食物中毒 菲国女商人 狮城求医获重生 | 中國報 China Press

EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with international trial site in Singapore to follow – BioSpace

Cholangiocarcinoma: Understanding this rare liver disease | 365 Cancer Prevention Society (365cps.org.sg)

Rules on cancer treatment financing in Singapore can be improved | The Straits Times

Private hospitals facing bed crunch, lack of manpower to keep all wards open | The Straits Times

Track 2 afternoon session, talking about refining the Standard of Care in mCRC: The Evidence & The Management

Oncoshot Enters Into MOU With Singapore Clinical Research Institute

Dr Choo Su Pin, Adjunct Associate Professor, Oncology Academic Clinical Programme, SingHealth Duke-NUS

Liver cancer top cause of cancer death among men in their 40s and 50s

Immunotherapy for Hepatocellular Carcinoma

Colorectal Cancer – Doctor Q&A​

Speech by Dr Lam Pin Min, Senior Minister of State for health, at the opening ceremony of European Society for Medical Oncology Asia 2018 Congress

Influence: Dr Choo Su Pin, Singapore Society of Oncology

New two-pronged method to fight deadly liver cancer

Liver cancer patients wanted for new clinical trial

Learning more about Liver Cancer

Drink Coffee, Fight Cancer

Dr Choo Su Pin – I run for my cancer patients

Medical experts in Singapore combine two treatments to treat liver cancer

Dr Choo Su Pin on ongoing Phase III EMERALD-1 study for cancer patients with intermediate stage HCC

MoneyFM 89.3 podcast: Dr Choo Su Pin – Health Suites: A new era of personalised medicine and targeted therapies

The Daily Star: Dr Choo Su Pin enlightens on Gastrointestinal Cancers

Singapore study introduces new strategy to treat advanced liver cancer

Clinical Trials

-

Clinical Trials

No.Tumor TypeStageStudy TitlePrincipal InvestigatorDetailsStatus
1Lung CancerIVA Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung CancerDr Toh Chee Keong#NCT04262856Open
2Breast cancerIVA Randomized, multicentre, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of ER(+), HER(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced diseaseDr Lynette Ngo#NCT04478266Open
3Hepatocellular carcinomaIVA Phase III, Randomized Double-blind, Placebo-controlled, Multicentre Study of Transarterial Chemoembolization (TACE) in Combination With either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)Dr Choo Su Pin#NCT03778957

Emerald-1 Trial Patient Information
Open
4Endometrial cancer IVA Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer(DUO-E)Dr Lynette Ngo#NCT04269200Open
5Gastric cancerIVA Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined with Chemotherapy versus Placebo Combined with Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerDr Choo Su Pin#NCT04139135Closed

Open chat
Need help?
Hello! Welcome to Curie Oncology!
How can we help you?